Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Receivables - Net (2024 - 2025)

Historic Receivables - Net for ARS Pharmaceuticals (SPRY) over the last 2 years, with Q3 2025 value amounting to $36.5 million.

  • ARS Pharmaceuticals' Receivables - Net rose 461552.39% to $36.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.5 million, marking a year-over-year increase of 461552.39%. This contributed to the annual value of $8.2 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Receivables - Net stood at $36.5 million, which was up 461552.39% from $25.1 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Receivables - Net ranged from a high of $36.5 million in Q3 2025 and a low of $773000.0 during Q3 2024